|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pilleron S, Soto-Perez-de-Celis E, Vignat
J, Ferlay J, Soerjomataram I, Bray F and Sarfati D: Estimated
global cancer incidence in the oldest adults in 2018 and
projections to 2050. Int J Cancer. 148:601–608. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu G, Cheresh P and Kamp DW: Molecular
basis of asbestos-induced lung disease. Annu Rev Pathol. 8:161–187.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choi WI, Park SH, Park BJ and Lee CW:
Interstitial lung disease and lung cancer development: A 5-year
nationwide population-based study. Cancer Res Treat. 50:374–381.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seijo LM and Zulueta JJ: Understanding the
links between lung cancer, COPD, and emphysema: A Key to more
effective treatment and screening. Oncology (Williston Park).
31:93–102. 2017.PubMed/NCBI
|
|
7
|
Ben Amar J, Ben Safta B, Zaibi H, Dhahri
B, Baccar MA and Azzabi S: Prognostic factors of advanced stage
non-small-cell lung cancer. Tunis Med. 94:360–367. 2016.PubMed/NCBI
|
|
8
|
Naylor EC: Adjuvant therapy for stage I
and II non-small cell lung cancer. Surg Oncol Clin N Am.
25:585–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Liu L and Song X, Wang K, Niu L, Xie
L and Song X: TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12
as novel biomarkers for lung cancer diagnosis and progression
prediction. J Cancer Res Clin Oncol. 147:1609–1622. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maly V, Maly O, Kolostova K and Bobek V:
Circulating tumor cells in diagnosis and treatment of lung cancer.
In Vivo. 33:1027–1037. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong X, Chang M and Song X, Ding S, Xie L
and Song X: Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as
potential biomarkers for early diagnosis of non-small cell lung
cancer. Thorac Cancer. 12:539–548. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iqbal MA, Arora S, Prakasam G, Calin GA
and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways
and therapeutic relevance. Mol Aspects Med. 70:3–20. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res. 34:(Database Issue).
D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Ren L, Li S, Li W, Zheng X, Yang Y,
Fu W, Yi J, Wang J and Du G: The biology, function, and
applications of exosomes in cancer. Acta Pharm Sin B. 11:2783–2797.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang D and Qu D: Early diagnostic and
prognostic value of serum exosomal miR-1246 in non-small cell lung
cancer. Int J Clin Exp Pathol. 13:1601–1607. 2020.PubMed/NCBI
|
|
17
|
de Rie D, Abugessaisa I, Alam T, Arner E,
Arner P, Ashoor H, Åström G, Babina M, Bertin N, Burroughs AM, et
al: An integrated expression atlas of miRNAs and their promoters in
human and mouse. Nat Biotechnol. 35:872–878. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Solé C and Lawrie CH: MicroRNAs in
metastasis and the tumour microenvironment. Int J Mol Sci.
22:48592021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Starega-Roslan J, Koscianska E, Kozlowski
P and Krzyzosiak WJ: The role of the precursor structure in the
biogenesis of microRNA. Cell Mol Life Sci. 68:2859–2871. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shang R, Baek SC, Kim K, Kim B, Kim VN and
Lai EC: Genomic clustering facilitates nuclear processing of
suboptimal Pri-miRNA loci. Mol Cell. 78:303–316.e4. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yeom KH, Lee Y, Han J, Suh MR and Kim VN:
Characterization of DGCR8/Pasha, the essential cofactor for Drosha
in primary miRNA processing. Nucleic Acids Res. 34:4622–4629. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alarcón CR, Lee H, Goodarzi H, Halberg N
and Tavazoie SF: N6-methyladenosine marks primary microRNAs for
processing. Nature. 519:482–485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Wang Z and Gemeinhart RA:
Progress in microRNA delivery. J Control Release. 172:962–974.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsuyama H and Suzuki HI: Systems and
synthetic microRNA biology: From biogenesis to disease
pathogenesis. Int J Mol Sci. 21:1322019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haneklaus M, Gerlic M, O'Neill LA and
Masters SL: miR-223: Infection, inflammation and cancer. J Intern
Med. 274:215–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang J, Han L, Yu J, Li H and Li Q:
miR-224 aggravates cancer-associated fibroblast-induced progression
of non-small cell lung cancer by modulating a positive loop of the
SIRT3/AMPK/mTOR/HIF-1α axis. Aging (Albany NY). 13:10431–10449.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu L, Chen Y, Liu J, Nie K, Xiao Y and Yu
H: MicroRNA-629 promotes the tumorigenesis of non-small-cell lung
cancer by targeting FOXO1 and activating PI3K/AKT pathway. Cancer
Biomark. 29:347–357. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiong J, Xing S, Dong Z, Niu L, Xu Q, Li
Y, Liu P and Yang P: miR-654-3p suppresses cell viability and
promotes apoptosis by targeting RASAL2 in non-small-cell lung
cancer. Mol Med Rep. 23:1242021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du H, Bao Y, Liu C, Zhong A, Niu Y and
Tang X: miR-139-5p enhances cisplatin sensitivity in non-small cell
lung cancer cells by inhibiting cell proliferation and promoting
apoptosis via the targeting of homeobox protein Hox-B2. Mol Med
Rep. 23:1042021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pu R, Pu M, Huang H and Cui Y: MicroRNA
144 inhibits cell migration and invasion and regulates inflammatory
cytokine secretion through targeting toll like receptor 2 in
non-small cell lung cancer. Arch Med Sci. 17:1028–1037. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan C, Bai R, Gao Y, Jiang X, Li S, Sun
W, Li Y, Huang Z, Gong Y and Xie C: Effects of MicroRNA-195-5p on
biological behaviors and radiosensitivity of lung adenocarcinoma
cells via targeting HOXA10. Oxid Med Cell Longev. 2021:45222102021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu X, Wu G, Zhang H, Peng X, Huang B,
Huang M, Ding J, Mao C and Peng C: MiR-196b promotes the invasion
and migration of lung adenocarcinoma cells by targeting AQP4.
Technol Cancer Res Treat. 20:15330338209858682021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fang QY, Deng QF, Luo J and Zhou CC:
MiRNA-20a-5p accelerates the proliferation and invasion of
non-small cell lung cancer by targeting and downregulating KLF9.
Eur Rev Med Pharmacol Sci. 24:2548–2556. 2020.PubMed/NCBI
|
|
36
|
Korde A, Jin L, Zhang JG, Ramaswamy A, Hu
B, Kolahian S, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L,
et al: Lung endothelial MicroRNA-1 regulates tumor growth and
angiogenesis. Am J Respir Crit Care Med. 196:1443–1455. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma Z, Wei K, Yang F, Guo Z, Pan C, He Y,
Wang J, Li Z, Chen L, Chen Y and Xia Y: Tumor-derived exosomal
miR-3157-3p promotes angiogenesis, vascular permeability and
metastasis by targeting TIMP/KLF2 in non-small cell lung cancer.
Cell Death Dis. 12:8402021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang D, Cai L, Tian X and Li W: MiR-543
promotes tumorigenesis and angiogenesis in non-small cell lung
cancer via modulating metastasis associated protein 1. Mol Med.
26:442020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao G, Zhang Y, Zhao Z, Cai H, Zhao X,
Yang T, Chen W, Yao C, Wang Z, Wang Z, et al: MiR-153 reduces stem
cell-like phenotype and tumor growth of lung adenocarcinoma by
targeting Jagged1. Stem Cell Res Ther. 11:1702020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fang L, Cai J, Chen B, Wu S, Li R, Xu X,
Yang Y, Guan H, Zhu X, Zhang L, et al: Aberrantly expressed
miR-582-3p maintains lung cancer stem cell-like traits by
activating Wnt/β-catenin signalling. Nat Commun. 6:86402015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang L, Zhang X, Wang X, He M and Qiao S:
MicroRNA-224 promotes tumorigenesis through downregulation of
caspase-9 in triple-negative breast cancer. Dis Markers.
2019:73789672019.PubMed/NCBI
|
|
42
|
Fassan M, Cui R, Gasparini P, Mescoli C,
Guzzardo V, Vicentini C, Munari G, Loupakis F, Lonardi S, Braconi
C, et al: miR-224 Is significantly upregulated and targets
caspase-3 and caspase-7 during colorectal carcinogenesis. Transl
Oncol. 12:282–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li J, Liu X, Li C and Wang W: miR-224-5p
inhibits proliferation, migration, and invasion by targeting
PIK3R3/AKT3 in uveal melanoma. J Cell Biochem. 120:12412–12421.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Alhazzazi TY, Kamarajan P, Verdin E and
Kapila YL: SIRT3 and cancer: Tumor promoter or suppressor? Biochim
Biophys Acta. 1816:80–88. 2011.PubMed/NCBI
|
|
45
|
Tao F, Gu C, Li N, Ying Y, Feng Y, Ni D,
Zhang Q and Xiao Q: SIRT3 acts as a novel biomarker for the
diagnosis of lung cancer: A retrospective study. Medicine
(Baltimore). 100:e265802021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marinov M, Fischer B and Arcaro A:
Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol.
63:172–182. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhan P, Zhao S, Yan H, Yin C, Xiao Y, Wang
Y, Ni R, Chen W, Wei G and Zhang P: α-enolase promotes
tumorigenesis and metastasis via regulating AMPK/mTOR pathway in
colorectal cancer. Mol Carcinog. 56:1427–1437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lu X and Kang Y: Hypoxia and
hypoxia-inducible factors: Master regulators of metastasis. Clin
Cancer Res. 16:5928–5935. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen CY, Chen J, He L and Stiles BL: PTEN:
Tumor suppressor and metabolic regulator. Front Endocrinol
(Lausanne). 9:3382018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang G, Han J, Zhuang L, Li S, Gong Q and
Chen Y: Serum starvation induces cell death in NSCLC via miR-224.
Onco Targets Ther. 12:3953–3962. 2019.PubMed/NCBI
|
|
51
|
Endo M: The roles of ANGPTL families in
cancer progression. J UOEH. 41:317–325. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ,
Chen MW, Jeng YM, Chiou J, Yu P, Chen PS, et al: Angiopoietin-like
protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin
Invest. 123:1082–1095. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Han H, Pan B, Liang F, Wu L, Liu X, Yang Y
and Chen J: MiR-224 promotes lymphatic metastasis by targeting
ANGPTL1 in non-small-cell lung carcinoma. Cancer Biomark.
34:431–441. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhu JH, De Mello RA, Yan QL, Wang JW, Chen
Y, Ye QH, Wang ZJ, Tang HJ and Huang T: MiR-139-5p/SLC7A11 inhibits
the proliferation, invasion and metastasis of pancreatic carcinoma
via PI3K/Akt signaling pathway. Biochim Biophys Acta Mol Basis Dis.
1866:1657472020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Song M, Yin Y, Zhang J, Zhang B, Bian Z,
Quan C, Zhou L, Hu Y, Wang Q, Ni S, et al: MiR-139-5p inhibits
migration and invasion of colorectal cancer by downregulating AMFR
and NOTCH1. Protein Cell. 5:851–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qiu G, Lin Y, Zhang H and Wu D: miR-139-5p
inhibits epithelial-mesenchymal transition, migration and invasion
of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
Biochem Biophys Res Commun. 463:315–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pan X, Liu W, Chai Y, Wang J and Zhang Y:
Genetic and clinical characterization of HOXB2 in glioma. Onco
Targets Ther. 13:10465–10473. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Huang L, Cai JL, Huang PZ, Kang L, Huang
MJ, Wang L and Wang JP: miR19b-3p promotes the growth and
metastasis of colorectal cancer via directly targeting ITGB8. Am J
Cancer Res. 7:1996–2008. 2017.PubMed/NCBI
|
|
60
|
Li J, Zhu T, Weng Y, Cheng F, Sun Q, Yang
K, Su Z and Ma H: Exosomal circDNER enhances paclitaxel resistance
and tumorigenicity of lung cancer via targeting miR-139-5p/ITGB8.
Thorac Cancer. 13:1381–1390. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang Y, Zhong Y, Zhang C, Liao J and Wang
G: PM2.5 downregulates MicroRNA-139-5p and induces EMT in
bronchiolar epithelium cells by targeting Notch1. J Cancer.
11:5758–5767. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Donnem T, Andersen S, Al-Shibli K, Al-Saad
S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and
receptors in nonsmall cell lung cancer: Coexpression of Notch-1 and
vascular endothelial growth factor-A predicts poor survival.
Cancer. 116:5676–5685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liao YC and Lo SH: Tensins-emerging
insights into their domain functions, biological roles and disease
relevance. J Cell Sci. 134:jcs2540292021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Duan J, Wang L, Shang L, Yang S, Wu H,
Huang Y and Miao Y: miR-152/TNS1 axis inhibits non-small cell lung
cancer progression through Akt/mTOR/RhoA pathway. Biosci Rep.
41:BSR202015392021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hinsby AM, Berezin V and Bock E: Molecular
mechanisms of NCAM function. Front Biosci. 9:2227–2244. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yang B, Huang S, Chen H, Li R, Hou S, Zhao
J and Li Y: DNMT3B regulates proliferation of A549 cells through
the microRNA-152-3p/NCAM1 pathway. Oncol Lett. 23:112022.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang L, Zhou F, Zheng D, Wang D, Li X,
Zhao C and Huang X: FGF/FGFR signaling: From lung development to
respiratory diseases. Cytokine Growth Factor Rev. 62:94–104. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cheng Z, Ma R, Tan W and Zhang L: MiR-152
suppresses the proliferation and invasion of NSCLC cells by
inhibiting FGF2. Exp Mol Med. 46:e1122014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zong D, Liu X, Li J, Long Y, Ouyang R and
Chen Y: LncRNA-CCAT1/miR-152-3p is involved in CSE-induced
inflammation in HBE cells via regulating ERK signaling pathway. Int
Immunopharmacol. 109:1088182022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huang J, Lou J, Liu X and Xie Y: LncRNA
PCGsEM1 contributes to the proliferation, migration and invasion of
non-small cell lung cancer cells via acting as a sponge for
miR-152-3p. Curr Pharm Des. 27:4663–4670. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Trakunram K, Chaniad P, Geater SL,
Keeratichananont W, Chittithavorn V, Uttayamakul S, Buya S,
Raungrut P and Thongsuksai P: Serum miR-339-3p as a potential
diagnostic marker for non-small cell lung cancer. Cancer Biol Med.
17:652–663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen L, Li Y and Lu J: Identification of
circulating miR-762 as a novel diagnostic and prognostic biomarker
for non-small cell lung cancer. Technol Cancer Res Treat.
19:15330338209642222020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ge P, Cao L, Chen X, Jing R and Yue W:
miR-762 activation confers acquired resistance to gefitinib in
non-small cell lung cancer. BMC Cancer. 19:12032019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li
Y, Zhang J, Beer DG, Yang S and Chen G: Serum microRNA signature is
capable of early diagnosis for non-small cell lung cancer. Int J
Biol Sci. 15:1712–1722. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Reis PP, Drigo SA, Carvalho RF, Lopez Lapa
RM, Felix TF, Patel D, Cheng D, Pintilie M, Liu G and Tsao MS:
Circulating miR-16-5p, miR-92a-3p, and miR-451a in plasma from lung
cancer patients: Potential application in early detection and a
regulatory role in tumorigenesis pathways. Cancers (Basel).
12:20712020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jiang HG, Dai CH, Xu YP, Jiang Q, Xia XB,
Shu Y and Li J: Four plasma miRNAs act as biomarkers for diagnosis
and prognosis of non-small cell lung cancer. Oncol Lett.
22:7922021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lu S, Kong H, Hou Y, Ge D, Huang W, Ou J,
Yang D, Zhang L, Wu G, Song Y, et al: Two plasma microRNA panels
for diagnosis and subtype discrimination of lung cancer. Lung
Cancer. 123:44–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liao J, Shen J, Leng Q, Qin M, Zhan M and
Jiang F: MicroRNA-based biomarkers for diagnosis of non-small cell
lung cancer (NSCLC). Thorac Cancer. 11:762–768. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Xie H and Chen J, Lv X, Zhang L, Wu J, Ge
X, Yang Q, Zhang D and Chen J: Clinical value of serum and exhaled
breath condensate miR-186 and IL-1β levels in non-small cell lung
cancer. Technol Cancer Res Treat. 19:15330338209474902020.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Tulinsky L, Dzian A, Matakova T and Ihnat
P: Overexpression of the miR-143/145 and reduced expression of the
let-7 and miR-126 for early lung cancer diagnosis. J Appl Biomed.
20:1–6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu F, Li T, Hu P and Dai L: Upregulation
of serum miR-629 predicts poor prognosis for non-small-cell lung
cancer. Dis Markers. 2021:88199342021.PubMed/NCBI
|
|
82
|
Mahmudunnabi RG, Umer M, Seo KD, Park DS,
Chung JH, Shiddiky MJA and Shim YB: Exosomal microRNAs array sensor
with a bioconjugate composed of p53 protein and hydrazine for the
specific lung cancer detection. Biosens Bioelectron.
207:1141492022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang Z, Tang Y and Song X, Xie L, Zhao S
and Song X: Tumor-derived exosomal miRNAs as diagnostic biomarkers
in non-small cell lung cancer. Front Oncol. 10:5600252020.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhang Y, Zhang Y, Yin Y and Li S:
Detection of circulating exosomal miR-17-5p serves as a novel
non-invasive diagnostic marker for non-small cell lung cancer
patients. Pathol Res Pract. 215:1524662019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang
G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on
cancer biology and clinical applications. Mol Cancer. 17:1472018.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Xu Z, Wang Z, Sun H and Xin H: Evaluation
of exosomal miRNA in Blood as a potential diagnostic biomarker for
human non-small cell lung cancer. Med Sci Monit. 26:e9247212020.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Liu Q, Yu Z, Yuan S, Xie W, Li C, Hu Z,
Xiang Y, Wu N, Wu L, Bai L and Li Y: Circulating exosomal microRNAs
as prognostic biomarkers for non-small-cell lung cancer.
Oncotarget. 8:13048–13058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kanaoka R, Iinuma H, Dejima H, Sakai T,
Uehara H, Matsutani N and Kawamura M: Usefulness of plasma exosomal
MicroRNA-451a as a noninvasive biomarker for early prediction of
recurrence and prognosis of non-small cell lung cancer. Oncology.
94:311–323. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Dejima H, Iinuma H, Kanaoka R, Matsutani N
and Kawamura M: Exosomal microRNA in plasma as a non-invasive
biomarker for the recurrence of non-small cell lung cancer. Oncol
Lett. 13:1256–1263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Grimolizzi F, Monaco F, Leoni F, Bracci M,
Staffolani S, Bersaglieri C, Gaetani S, Valentino M, Amati M,
Rubini C, et al: Exosomal miR-126 as a circulating biomarker in
non-small-cell lung cancer regulating cancer progression. Sci Rep.
7:152772017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liu W, Chen S and Liu B: Diagnostic and
prognostic values of serum exosomal microRNA-21 in children with
hepatoblastoma: A Chinese population-based study. Pediatr Surg Int.
32:1059–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wang W, Wu LR, Li C, Zhou X, Liu P, Jia X,
Chen Y and Zhu W: Five serum microRNAs for detection and predicting
of ovarian cancer. Eur J Obstet Gynecol Reprod Biol X.
3:1000172019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wu Q, Yu L, Lin X, Zheng Q, Zhang S, Chen
D, Pan X and Huang Y: Combination of serum miRNAs with serum
exosomal miRNAs in early diagnosis for non-small-cell lung cancer.
Cancer Manag Res. 12:485–495. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li M, Shan W, Hong B, Zou J, Li H, Han D,
Zhang Y, Li L, Li D and Lin W: Circulating miR-92b and miR-375 for
monitoring the chemoresistance and prognosis of small cell lung
cancer. Sci Rep. 10:127052020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhao YL, Zhang JX, Yang JJ, Wei YB, Peng
JF, Fu CJ, Huang MH, Wang R, Wang PY, Sun GB and Xie SY: MiR-205-5p
promotes lung cancer progression and is valuable for the diagnosis
of lung cancer. Thorac Cancer. 13:832–843. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Wang X, Jiang X, Li J, Wang J, Binang H,
Shi S, Duan W, Zhao Y and Zhang Y: Serum exosomal miR-1269a serves
as a diagnostic marker and plays an oncogenic role in non-small
cell lung cancer. Thorac Cancer. 11:3436–3447. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Zhou C, Chen Z, Zhao L, Zhao W, Zhu Y, Liu
J and Zhao X: A novel circulating miRNA-based signature for the
early diagnosis and prognosis prediction of non-small-cell lung
cancer. J Clin Lab Anal. 34:e235052020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yang Y, Jia Y, Xiao Y, Hao Y, Zhang L,
Chen X, He J, Zhao Y and Qian Z: Tumor-targeting anti-MicroRNA-155
delivery based on biodegradable poly(ester amine) and hyaluronic
acid shielding for lung cancer therapy. Chemphyschem. 19:2058–2069.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai
X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived
exosomal miRNA as potential diagnostic biomarkers for early-stage
non-small cell lung cancer using next-generation sequencing. Clin
Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Migdalska-Sęk M, Modrzewska B, Kordiak J,
Pastuszak-Lewandoska D, Kiszałkiewicz JM, Bielec F, Antczak A and
Brzeziańska-Lasota E: Diagnostic value of PPARδ and miRNA-17
expression levels in patients with non-small cell lung cancer. Sci
Rep. 11:241362021. View Article : Google Scholar : PubMed/NCBI
|
